Treatment of Non-infectious Disease

Q1 — Band 6 sample response and marking criteria (8 marks)

Molecular defect in F508del CF: The F508del mutation causes deletion of phenylalanine at position 508 of the CFTR protein. This prevents the protein from folding correctly in the endoplasmic reticulum — the misfolded protein is recognised and degraded by the cell's quality-control machinery (ERAD pathway) rather than trafficking to the apical epithelial membrane. Virtually no functional CFTR chloride channel reaches the surface, so Cl− cannot be secreted into the airway lumen, water does not follow by osmosis, and the airway surface liquid becomes dehydrated — producing the thick, viscous mucus that is the hallmark of CF pathology. [2 marks]

How Trikafta addresses this: Trikafta combines two corrector drugs (elexacaftor and tezacaftor) that bind to the F508del CFTR protein during folding in the ER and stabilise its structure, allowing more protein to fold correctly and traffic to the epithelial membrane, and one potentiator (ivacaftor) that binds the CFTR protein already at the membrane and increases the probability and duration of its channel-open state. This restores partial Cl− secretion — water follows osmotically — mucus is hydrated — mucociliary clearance is partially or substantially restored. Trikafta does not correct the gene mutation; it rescues the dysfunctional protein's function at the molecular level. [1 mark]

Clinical significance from data (Stimulus 1A): The outcomes data demonstrate profound clinical impact: lung function decline is substantially slowed or reversed (from approximately −2 percentage points/year to stable or improving), pulmonary exacerbation rates fell by ~63%, and the trajectory toward lung transplant — which defined CF for most of the 20th century — is projected to be largely avoidable for patients on Trikafta. Life expectancy, previously ~46–50 years, is projected to increase dramatically. This is not an incremental improvement — it is a transformation in disease trajectory that exceeds anything achieved by 30 years of symptomatic management. [1 mark]

Was molecular understanding "sufficient"? The 33-year gap: The claim is partially correct but "sufficient" overstates the case. Identifying the CFTR gene in 1989 was necessary — without mechanistic knowledge, rational drug design was impossible. However, the 33-year gap demonstrates that knowledge alone was not sufficient. Developing Trikafta additionally required: (i) resolving the three-dimensional structure of CFTR at the atomic level to identify drug-binding sites; (ii) high-throughput screening of millions of small molecules for CFTR-modulating activity; (iii) extensive medicinal chemistry to optimise compounds for efficacy, selectivity, and pharmacokinetic properties; (iv) Phase 1–3 clinical trials in thousands of patients; (v) regulatory review and PBS listing — all of which required decades and enormous financial investment. Molecular understanding initiated rational drug design; technical capacity, resources, and time translated understanding into medicine. [2 marks]

Applicability to Huntington's disease: The Trikafta approach (small-molecule protein function rescue) does not translate directly to Huntington's disease because the molecular defect is fundamentally different. CF involves loss-of-function of a correctable protein — restoring CFTR function is achievable by stabilising folding. HD involves a toxic gain-of-function mutation (expanded CAG repeat in huntingtin) producing a protein whose polyQ domain drives toxic aggregation in neurons. The solution is not to restore or stabilise the mutant protein's function — it is to reduce its production. Hence ASOs targeting the mutant HTT mRNA (reducing toxic huntingtin production) represent the appropriate therapeutic approach for HD. CRISPR gene editing (correcting the CAG expansion) would be the true molecular root-cause treatment for HD, but this requires delivery to neurons — a technically far harder problem than dosing a small-molecule drug. Each disease requires an approach matched to its specific molecular defect. [1 mark]

Evidence-based judgement: Mechanistic understanding is the necessary starting point for rational treatment development but is not sufficient alone. The CF example shows that when a molecular defect is tractable (correctable folding defect, accessible protein target, small-molecule intervention feasible), mechanistic knowledge eventually produces transformative therapy — but the pathway requires decades of additional technical and financial investment. For diseases where the defect is not "correctable" by small molecules — toxic protein aggregation, structural protein absence, transcription factor dysfunction — alternative approaches are needed. The relationship between mechanistic knowledge and effective therapy is enabling but not automatic. [1 mark]

Marking criteria:

• 2 marks — Accurately describes the F508del molecular defect (protein misfolding → ERAD degradation → absent membrane CFTR) AND explains how Trikafta's correctors + potentiator address this at the protein level (stabilise folding → membrane trafficking → channel open longer → Cl− secretion restored).
• 1 mark — Uses at least one piece of data from Stimulus 1A to make a specific statement about clinical significance (e.g. quotes the 63% exacerbation reduction, the life-expectancy projection, or the lung transplant impact).
• 2 marks — Addresses the 33-year gap substantively: identifies that gene identification in 1989 was necessary but not sufficient [1] AND names at least two specific additional requirements (protein structure determination, drug screening/chemistry, clinical trials, cost/access) [1].
• 1 mark — Correctly distinguishes the CF molecular problem (loss-of-function, correctable by small molecule) from HD (toxic gain-of-function, different therapeutic logic — reduce production via ASO or correct DNA via CRISPR, not stabilise function), and uses this to justify why the Trikafta approach cannot be directly applied to HD.
• 1 mark — Reaches an explicit, evidence-based judgement that evaluates the claim as partially correct — mechanistic understanding is necessary but not sufficient — and uses specific evidence to support this nuanced position.

Q2 — Band 6 sample response and marking criteria (7 marks)

Level of intervention: Option A (SGLT-2 inhibitor, empagliflozin): mechanism level — it reduces blood glucose by blocking glucose reabsorption in the renal tubule (glucosuria), but does not address insulin resistance or beta-cell exhaustion; these continue to drive disease. Option B (semaglutide, GLP-1 agonist): mechanism/root-cause interface — semaglutide stimulates insulin secretion in a glucose-dependent manner and suppresses glucagon, managing blood glucose. More importantly at this patient's BMI, its appetite-suppressing and weight-loss effects (~15–17% body weight in trials) can substantially reduce visceral fat, reduce adipokine-driven insulin resistance, and approach root-cause modification. The weight-loss component is genuinely root-cause; the glucose-management component is mechanism. Option C (dietary weight-management programme): root-cause level — targets visceral fat excess, the primary metabolic driver of T2D in this patient. Significant weight loss (targeting 15 kg) reduces visceral adipose tissue → adipokine normalisation → insulin receptor sensitisation restored → beta-cell recovery possible. [2 marks]

Comparison on 3+ criteria:

• Remission potential: A — minimal (~2 kg weight loss, glucosuria management — remission unlikely). B — moderate to high (15–17% weight loss in trials → real possibility of remission in a patient 3 years post-diagnosis with preserved beta-cell capacity). C — highest potential if 15 kg achieved (46% remission at 12 months in DiRECT).
• Access and logistics: A and B — prescribable by GP, dispensed locally; suitable for patient in regional town. C — intensive structured programme likely requires specialist team and regular contact with major diabetes centre (3 hours away), creating a significant access barrier for this patient.
• Mechanism of glucose control: A — glucosuria (kidney-level, glucose-lowering without affecting the insulin resistance drivers). B — GLP-1 mimicry (glucose-dependent insulin release + appetite suppression + satiety signals + gastric emptying delay + weight loss). C — visceral fat reduction → adipokine-mediated reversal of insulin resistance → beta-cell recovery (most physiologically complete).
• Cardiovascular benefit: Both B and A (SGLT-2 inhibitors) have demonstrated cardiovascular mortality benefit in trials, independent of glucose lowering — an important consideration for T2D patients with elevated cardiovascular risk. [1 mark for ≥3 criteria compared]

Root-cause option: Option C directly addresses the root cause — the visceral fat excess and adipokine-driven insulin resistance that drive T2D in this patient. Option B also has significant root-cause potential via weight loss. Option A manages a consequence (hyperglycaemia) without addressing insulin resistance. [1 mark]

Justified recommendation: For this patient, the optimal strategy is Option B combined with lifestyle modification elements. The access barrier to a structured intensive programme (Option C, 3 hours away) is a realistic impediment to achieving the protocol adherence that makes DiRECT-type programmes effective. Semaglutide (Option B) is prescribable locally, produces clinically significant weight loss (15–17%) that could independently achieve T2D remission in a patient this early in her disease course with strong motivation, and provides cardiovascular protection. It also addresses root cause via the weight-loss pathway. Option A could be added for additional glycaemic control if HbA1c targets are not met. Option C should not be ruled out — if access can be arranged, combining B and C could maximise remission probability. The recommendation is not "one treatment wins" but a pragmatic combination matched to this patient's geography, motivation, and disease stage. [2 marks]

Explicit note on misconception: This is not a case of "drugs vs lifestyle" being a binary choice. In this patient, lifestyle elements are embedded in semaglutide's mechanism (appetite suppression and weight loss), and lifestyle change should accompany any pharmacological option. [1 mark for reaching explicit non-one-winner judgement]

Marking criteria:

• 2 marks — Correctly classifies all three options by intervention level with justification: A = mechanism (glucosuria, not root cause); B = mechanism-to-root-cause depending on weight loss; C = root cause (visceral fat → insulin resistance pathway). Award 1 mark for any two correctly classified and justified.
• 1 mark — Compares options on at least three explicitly named, patient-relevant criteria (e.g. remission potential, access/logistics, mechanism, cardiovascular benefit, beta-cell recovery, patient adherence).
• 1 mark — Correctly identifies Option C (or B via its weight-loss mechanism) as the root-cause option and explains the biological mechanism: visceral fat reduction → adipokine normalisation → insulin receptor sensitisation restored → beta-cell recovery.
• 2 marks — Reaches a justified recommendation that: (i) accounts for the patient's specific access barrier (regional location, 3 hrs from centre) as a real constraint on Option C [1]; and (ii) integrates the evidence for B's weight-loss / remission potential into a pragmatic recommendation that is neither "drugs always better" nor "lifestyle always better" [1].
• 1 mark — Explicitly states that this is not a one-winner judgement — e.g. recommends combination, or frames the answer as context-dependent, or notes that remission is possible through multiple pathways.